Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I agree without JR's to share the experience, it would be no fun at all watching the sp go up 10% in a morning.
Paul
My rule of thumb is that big up moves will hold end if there is no news associated with it. So, I expect PPHM to close up significantly today.
However, if the cc does come up with some news with serious financial implications, we will be back below $2 next week. Maybe this time Peregrine will actually come through.
Paul
Now is the time when the pessimists have to really get creative to explain why the share price going up is a bad thing and can't possibly last. Go to it boys.
Paul
In other words this is what Avastin should have been, instead of the crude tool it is.
Paul
I believe it was previously announced that Peregrine/Affitech negotiated a deal whereby Peregrine would reinvest certain cash payments due from Affitech back into the R84 project.
Paul
Perhaps you might have more impact on this board if you weren't so prolific.
Paul
Refering to Peregrine "PR machine" is amazing. For many years posters here have bitterly complained about the absence of any serious PR action from Peregrine.
By the way, the stock price tanking at the end of the day usually happens on good news days. On no news days the spike typically holds up.
Paul
If I read the board sentiment, i.e. the most frequent posters, good news today is just a distraction from the underlying bad news of prior years and should be discounted accordingly. It certainly is reassuring to know that past performance is a completely reliable predictor of the future.
Paul
I agree for the most part with your general impression that Bavi was not as effective as some of us had hoped. However, I think the comparison with Avastin might be misinterpreted on this board.
I don't think the comparison was meant to show that Bavi should replace Avastin. I think the comparison was meant to show that the mechanism of action used by Bavi is equally or more effective than an already approved part of the SOC with a better safety profile.
If this was true, Bavi should have a fighting chance for approval and success in patient treatment.
Paul
Bavituximab is being tested in human beings in the United States on lung, liver, pancreatic, prostate and breast cancers as well as hepc by company sponsored and independent research docs.
I've bet my money that it will improve on the SOC in at least one of these, which IMO will trigger a lucrative partnership agreement or outright buyout. If I'm wrong, I'll lose a lot money. If I'm right I'll make much more money than I've wagered.
I enjoy the ride, despite the well-meaning(?) and realistic(?) pessimistic opinions I encounter regarding PPHM.
Happy in my investments,
Paul
I will keep dreaming until we get trial results, which should be over the next 6-9 mos. The wait will soon be over. We will know one way or the other. I just hope all the recently hired talent knew what they were doing when they signed on with Peregrine.
Paul
The test was a signal seeking trial in a third world country fostered by a company that has skated along the edge of bankruptcy for years. The only realistic purpose of this trial was to learn whether the company had a future, period. The results were good enough; PPHM is still here today and is now doing meaningful trials.
Criticizing those trials is looking at the rear view mirror; the real action can only be viewed through the windshield where we will see if PPHM continues to move forward or hits a brick wall.
Paul
Thanks for the injection of objective information - a welcome respite from the litany of management's alleged ineptitude.
Paul
What miscues? I have followed these trials for years, and I am not aware of any. As John McEnroe would say, "You can't be serious!"
Paul
I don't care if we ever hear from him again if Bavi and Cotara move the share price higher, much higher.
Paul
Another interesting point regarding "competition" for Cotara and Bavi. Their target cancers are such lethal diseases that I'm sure the doctors and patients want as many affective treatment modalities as they can get. This is clearly not a zero sum game.
Paul
Another point of interest on the GBM trial.
http://www.sciencedaily.com/releases/2011/06/110621114153.htm
In this study GMB patients who exercised regularly survived 20 months instead of the usual 13. So, maybe the patients in the samll phase 1 study were just more physically active.
Paul
One point of interest is the GBM patients were newly diagnosed. I believe the Cotara patients had already relapsed from previous treatment.
Paul
Isn't this study still recruiting? Can they produce results before they complete recruiting?
Paul
Can it be that those of us who have bought into the Peregrine story are so wrong about it? Year after year the share price continues to trend down. Even though there are promising signs of progress toward commercialization of Cotara and Bavi?
It has been a long haul to reach this miserable share price. I have to hope Peregrine is going to start showing signs of life soon.
Paul
Aren't we due for a quarterly conference call soon?
Paul
Even if these vaccines pan out, it will more than a few years from now. It's a long way from the mice to the people.
Paul
If I was a cancer drugs saleman, I'd be salivating at the chance to add a sale of Bavi at thousands a pop to my existing inventory of drugs. What a great way to increase my commissions!
Which companies are the biggest providers of cancer drugs? I hope Peregrine can ink a deal with one of them in the next twelve months. Then, we will leave this daytraders playground for good.
I have followed R84 or 2C3 or whatever it has been called for years, but I don't think we will be see much cash from Affitech for years. I am more than willing to be wrong here.
Paul
I wonder if US study results will be better due to the generally healthier population in the USA, no slight to our Indian brothers and sister.
Paul
68 million shares outstanding and about half of one percent dumped today. I agree if they know something we don't, it's bad. Otherwise, I'm not sure why I should care. I have no plans to sell until something actually affecting Peregrine's prospects to succeed or fail comes to light. That said, it is not fun to watch.
Paul
I apologize to the daytraders who I encouraged to buy last week in hopes of a bounce this week. Don't see no bounce today. Just another 'no news deep drop'.
Paul
It is obvious that Peregrine management does not care about anything but executing their 'business plan'. The business plan, as I understand it, is to push Cotara and Bavi through clinical trials until partners are competing for either, both or the company as a whole. I wish they gave a rats ass about the share price, but I have seen precious little evidence that they do.
If they are successful in their approach, and they can find smart people to handle the partnerings and or sale, we will be all right. Otherwise, we won't.
Paul
A quick review of Peregrine's management team as shown on the website shows a lot of new names. Maybe the augmented management team will be able to achieve what the old team couldn't.
Perhaps they can turn credibility with the FDA into credibility with Big Pharma and the stock market. While others are running out of patience with Peregrine, it could be that a new chapeter is just getting started.
I love it when good news, however minor, is put in a negative light. It shows unitiated visitors how to analyze the biases of such posters.
Paul
Who cares how long it takes? The important thing is the Cotara presentation is in a meaningful forum.
Paul
I guess we are due for a conference call pretty soon. I'd like to think that someone will rub managments noses in the poor share price movement. The 'we are building value with the trials' has not panned out yet. I am optimistic, but this dismal share price performance should be on management's todo list. As they do not have the skills to address it, perhaps they need to spend some of our hard earned money to employ an investment firm that can actually help.
I would also like to hear them explain what all the new hiring is about. I hope there are immediate prospects to turn this brain power into something that could lift the share price.
We have shown them our money for the last ten years, it is about time they show us that our money has done more than support research scientists and fund management salaries.
Paul
Sadly, there may be more and better buying opportunities ahead. However, if the long-suffering optimists are even half right, this is could be a very good buying opportunity.
Paul
OK daytraders! Here's the blue light special of the day. Buy a new cancer treatment for pennies. Sell next week for an easy 10% gain.
Paul
I find it strange that the closer Cotara and Bavi get to the finish line, the lower the stock price gets.
Paul
You may be right.
Good for you BC. I hope you are with us on the days(may they be soon) when we longs will no longer look so dumb.
Paul
If Peregrine management believed that Cotara and Bavi were not commercially viable, I think they would cut costs aggressively to buy time to postpone the loss of their jobs or to come up with some new prospects. Instead, they are hiring like crazy and running as many trials as possible.
My conclusion, they believe in Cotara and Bavi. If you agree, gird up your loins and buy more on these "irrational" dips. All said with fingers crossed and IMNSHO.
Paul
And who would we have partnered with? And what would they have paid us, for what?
It's easy to make claims. It's appreciably harder to actually operate a long shot business on a shoe string through difficult times.
I give Peregrine management credit for bringing Cotara and more importantly Bavi this far.
Paul
Gary Carter has GBM. I hope his doctors are aware of the Cotara trials.
Paul
Dr. Thorpe is very publicly staking his reputation on the anti-PS paradigm of Bavi. These slides certainly show he has carefully studied the MOA. If he is correct regarding the power of this approach, the current trials will bear fruit. Patients will benefit and we longs will be there to cash in.
I know I've said it before, but we will know within 12 months whether Dr. Thorpe's lab work actually helps people and consequently whether Peregrine will make it or not.
Paul